About PolpharmaWe are the largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market. We actively operate in the markets of Central and Eastern Europe, the Caucasus and Central Asia.
Sustainable development/ESG“We help people live healthy lives in a healthy world”. This is our mission, which reflects Polpharma’s priorities. We provide patients with high-quality, effective, safe and accessible products while operating responsibly in the society, the environment and with respect to key stakeholders.
CareerPolpharma's development is possible only thanks to the commitment of our employees as well as the involvement of students and graduates in various business areas.
PRICE INQUIRY No. SEMA/77/PR142493/2026 – being conducted as a market assessment study13 February 2026In connection with the implementation of the project titled “Design and development of an innovative solution – a drug from the group of GLP-1 receptor… read more
Company News Polpharma SA launches a project under the STEP initiative12 February 2026“The European Commission is implementing the STEP programme to support the development of breakthrough critical technologies that can strengthen the EU economy and reduce its… read more
PRICE INQUIRY No. NUSI132_PR142701_2026 – being conducted as a market assessment study22 January 2026In connection with the implementation of the project titled “Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological… read more
REQUIRE FOR QUOTATION No. NUSI_131A_PR137000_2026 – being conducted as a market assessment study15 January 2026In connection with the implementation of the project entitled “Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological… read more
REQUIRE FOR QUOTATION No. NUSI_131_PR137000_2025 – being conducted as a market assessment study23 December 2025In connection with the implementation of the project entitled “Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological… read more
